^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BAT8010

    i
    Other names: BAT8010, BAT 8010, BAT-8010
    Associations

    News

    Trials
    Company:
    Bio-Thera Solutions
    Drug class:
    Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    9ms
    A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors (clinicaltrials.gov)
    P1/2, N=216, Recruiting, Bio-Thera Solutions | Trial primary completion date: Dec 2024 --> Nov 2026
    Trial primary completion date
    |
    BAT1006 • BAT8010
    1year
    A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors (clinicaltrials.gov)
    P1/2, N=216, Recruiting, Bio-Thera Solutions | N=108 --> 216
    Enrollment change • Combination therapy • Metastases
    |
    BAT1006 • BAT8010
    over1year
    A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors (clinicaltrials.gov)
    P1/2, N=108, Recruiting, Bio-Thera Solutions | Not yet recruiting --> Recruiting | Trial primary completion date: May 2024 --> Dec 2024
    Enrollment open • Trial primary completion date • Combination therapy • Metastases
    |
    BAT1006 • BAT8010
    over1year
    An Evaluation of BAT 8010 for Injection in Combination With BAT 1006 in Locally Advanced or Metastatic Entities Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of the Tumor in Patients Multicenter, Open Phase Ib/IIa Clinical Study (clinicaltrials.gov)
    P1/2, N=108, Not yet recruiting, Bio-Thera Solutions
    New P1/2 trial • Combination therapy • Metastases
    |
    BAT1006 • BAT8010
    over2years
    Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients (clinicaltrials.gov)
    P1, N=109, Recruiting, Bio-Thera Solutions
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    BAT8010